ArticleCardiology and therapy2026
Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT.
Article in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01994889 (A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A multicenter, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of daily oral dosing of tafamidis meglumine (pf-06291826) 20 mg or 80 mg in comparison to placebo in subjects diagnosed with transthyretin cardiomyopathy (ttr-cm)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of results of the phase 3 study ATTR-ACT. This post hoc analysis from ATTR-ACT evaluated the effect of tafamidis on transthyretin (TTR) concentration and explored the potential relationship between changes in TTR concentration at month 1 (early ΔTTR) and all-cause mortality (ACM).
methodsPatients with ATTR-CM treated with tafamidis 80 mg or placebo in ATTR-ACT who survived until month 1 were included. The independent association between early ΔTTR and ACM at month 30 was evaluated using univariate analyses, including a logistic model for ACM incidence and a Cox model for time to ACM. Baseline variables significantly influencing this relationship were identified using backward selection and included as covariates (baseline TTR concentration and National Amyloidosis Centre stage) in a multivariable Cox model.
resultsTafamidis 80 mg produced a 36.3% mean increase in TTR concentration by month 1 (mean [SD] change 7.3 [3.9] mg/dL) that was sustained through month 30, whereas placebo showed minimal change at month 1 (mean change [SD] - 0.02 [2.9] mg/dL) and throughout the study period. Logistic regression showed early ΔTTR was associated with reduced odds of ACM by month 30 only in patients treated with tafamidis; every 5 mg/dL increase correlated with a 45.0% reduction in odds of ACM (p = 0.0193). In univariate analysis, every 1 mg/dL increase in TTR concentration at month 1 in patients treated with tafamidis was associated with a 9.3% hazard reduction in ACM (hazard ratio 0.907; 95% CI 0.837-0.983, p = 0.0174). Multivariable analysis showed an 8.7% reduction in hazard of ACM for each 1 mg/dL increase.
conclusionsTafamidis was associated with an early increase in TTR concentration that was sustained through month 30, and early increases correlated with reduced ACM. However, mechanisms underlying TTR concentration increases and their clinical significance remain unclear. Graphical abstract available for this article.
trial registrationClinicalTrials.gov identifier NCT01994889.
Indexed as
Identifiers
42658464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.